ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 28 of 44
Up
УЖМБС 2019, 4(2): 187–194
https://doi.org/10.26693/jmbs04.02.187
Clinical Medicine

The Intensity in Pathogenesis of Mutual Burden of Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease with Obesity

Khukhlina O. S., Antoniv A. A., Voevidka O. S., Kotsyubiychuk Z. Ya., Gaidichuk V. S., Andrusyak O. V.
Abstract

The purpose of the study was to find out the possible intensity in the pathogenesis of the mutual burden of non-alcoholic fatty liver disease on the background of obesity, depending on its type and the presence of a comorbid chronic kidney disease. Material and methods. 384 patients with non-alcoholic fatty liver disease were examined: 84 of them with non-alcoholic fatty liver disease with obesity of the 1st degree (group 1), which contained 2 subgroups: 32 patients with non-alcoholic steatosis and 52 patients with non-alcoholic steatohepatitis; 270 patients with non-alcoholic fatty liver disease with comorbid obesity of the 1st degree and chronic kidney disease І-ІІІ stage (group 2), including 110 patients with non-alcoholic steatosis and 160 patients with non-alcoholic steatohepatitis. The control group consisted of 90 patients with chronic kidney disease of the І-ІІІ stage with normal body weight (group 3). Results and discussion. The study showed that the most significant metabolic changes for the development of non-alcoholic fatty liver disease on the background of obesity and chronic kidney disease are likely postprandial hyperglycemia, hyperinsulinemia, increased glycated hemoglobin, and primary tissue insulin resistance. The reason for the metabolic syndrome progression on the background of non-alcoholic fatty liver disease and chronic kidney disease is lipid distress syndrome with an increase in proatherogenic lipoproteins, anti-atherogenic high-density lipoproteins. The leading role in the development and progression of steatohepatitis is the disorders of the hepatic circulation that results in an increase in blood TG. Conclusions. The development of non-alcoholic fatty liver disease in patients with chronic kidney disease and obesity is accompanied by a significant disorder of hyperlipidemia with the highest among the groups compared with the increase in the content of low density proatherogenic lipoproteins, the probable decrease in anti-atherogenic high-density lipoproteins and the increase in the atherogenicity index.

Keywords: nonalcoholic fatty liver disease, chronic kidney disease, obesity

Full text: PDF (Ukr) 235K

References
  1. Babak OYa, Kolesnikova EV, Syitnik KA. Profilakticheskie meropriyatiya pri nealkogolnoy zhirovoy bolezni pecheni: suschestvuet li sposob snizit risk razvitiya zabolevaniya? [Preventive measures for non-alcoholic fatty liver disease: is there a way to reduce the risk of the disease?]. Suchasna gastroenterol. 2013; 3(71): 103-9. [Russian]
  2. Kolesnyk MO, Gholubchykov MV, Sajdakova NO. ta in. Klasyfikacija khvorob sechovoji systemy ta vedennja reghionaljnykh ta nacionaljnogho rejestriv khvorykh z khronichnoju khvoroboju nyrok: Metod rekomendaciji MOZ Ukrajiny, AMN Ukrajiny, Ukr Centr naukovoji med informaciji i patentno-licenzijnoji roboty. K; 2006. 24 s. [Ukrainian]
  3. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10: 330-44. https://www.ncbi.nlm.nih.gov/pubmed/23507799. https://doi.org/10.1038/nrgastro.2013.41
  4. Baumgarten M, Gehr T. Chronic kidney disease: detection and evaluation. American Family Physician. 2011; 84(10): 1138-48.
  5. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, et al. NASH Clinical Research Network (CRN) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011; 53(3): 810-20. https://www.ncbi.nlm.nih.gov/pubmed/21319198. https://www.ncbi.nlm.nih.gov/pmc/articles/3079483. https://doi.org/10.1002/hep.24127
  6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012; 107: 811–26. https://www.ncbi.nlm.nih.gov/pubmed/22488764. https://doi.org/10.1002/hep.25762
  7. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol. 2013; 10 (11): 666–75. https://www.ncbi.nlm.nih.gov/pubmed/24061203. https://doi.org/10.1038/nrgastro.2013.175
  8. Cohen E, Nardi Y, Krause I, Goldberg E, Milo G, Garty M, Krause I. A longitudinal assessment of the natural rate of decline in renal function with age. J Nephrol. 2014; 27(6): 635-41. https://www.ncbi.nlm.nih.gov/pubmed/24643437. https://doi.org/10.1007/s40620-014-0077-9
  9. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011; 43: 617-49. https://www.ncbi.nlm.nih.gov/pubmed/21039302, https://doi.org/10.3109/07853890.2010.518623
  10. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013; 59(4): 859-71. https://www.ncbi.nlm.nih.gov/pubmed/23751754. https://doi.org/10.1016/j.jhep.2013.05.044